Mammographic screening and risk factors for breast cancer

American Journal of Epidemiology

Volumn 170, Issue 11, 2009, Pages 1422-1432

  Cook, Nancy R ^a,b   Rosner, Bernard A ^a,b   Hankinson, Susan E ^a,b   Colditz, Graham A ^b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast neoplasms; Hormone replacement therapy; Mammography; Mass screening; Probability weighting; Risk factors

Indexed keywords

CHOLESTEROL;

BODY MASS; CANCER; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; DISEASE INCIDENCE; HEALTH SURVEY; HORMONE; NUMERICAL MODEL; RISK FACTOR; SMOKING; TEMPORAL ANALYSIS; WOMENS HEALTH;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; BREAST CANCER; CALCIUM INTAKE; CANCER RISK; CANCER SCREENING; CHOLESTEROL BLOOD LEVEL; FAMILY HISTORY; FEMALE; HORMONAL THERAPY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MAMMOGRAPHY; NURSE; OSTEOARTHRITIS; PHYSICAL ACTIVITY; POSTMENOPAUSE; PREDICTION; RISK FACTOR; SMOKING; STATISTICAL MODEL; VITAMIN INTAKE;

ADULT; BIAS (EPIDEMIOLOGY); BREAST NEOPLASMS; COHORT STUDIES; CONFIDENCE INTERVALS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; LOGISTIC MODELS; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; PARITY; PREGNANCY; RISK FACTORS; SMOKING;

EID: 70849125491     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwp304     Document Type: Article

References (34)

1. Use of mammograms among women aged > 40 years-United States, 2000-2005. MMWRMorb Mortal WklyRep. 2007;56(3): 49-51.
2. Steinberg KK, Thacker SB, Smith SJ, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA. 1991;265(15):1985-1990
3. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 1997;350(9084):1047-1059.
4. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995;332(24):1589-1593.
5. Edwards QT, Li AX, Pike MC, et al. Ethnic differences in the use of regular mammography: the multiethnic cohort. Breast Cancer Res Treat. 2009;115(1):163-170.
6. Schairer C, Byrne C, Keyl PM, et al. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer. Cancer Causes Control. 1994;5(6):491-500.
7. Bynum JP, Braunstein JB, Sharkey P, et al. The influence of health status, age, and race on screening mammography in elderly women. Arch Intern Med. 2005;165(18):2083-2088.
8. Lipscombe LL, Hux JE, Booth GL. Reduced screening mammography among women with diabetes. Arch Intern Med. 2005;165(18):2090-2095.
9. Berz D, Sikov W, Colvin G, et al. 'Weighing in' on screening mammography. Breast Cancer Res Treat. 2009;114(3): 569-574.
10. Robins JM, Greenland S. Identifiability and exchangeability for direct and indirect effects. Epidemiology. 1992;3(2): 143-155.
11. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784-1792.
12. Weiss NS. Adjusting for screening history in epidemiologic studies of cancer: why, when, and how to do it. Am J Epidemiol. 2003;157(11):957-961.
13. Joffe MM. Invited commentary: screening as a nuisance variable in cancer epidemiology: methodological considerations. Am J Epidemiol. 2003;157(11):962-964.
14. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879-1886.
15. Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am J Epidemiol. 2000;152(10):950-964.
16. Barlow WE, White E, Ballard-Barbash R, et al. Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst. 2006;98(17): 1204-1214.
17. Tice JA, Cummings SR, Smith-Bindman R, et al. Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med. 2008;148(5):337-347
18. Sas, version 9.1. Cary, NC: SAS Institute, Inc 2007
19. Colditz GA, Rosner BA, Chen WY, et al. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst. 2004;96(3):218-228.
20. Greenland S, Pearl J, Robins JM. Causal diagrams for epide-miologic research. Epidemiology. 1999;10(1):37-48.
21. Joffe MM, Byrne C, Colditz GA. Postmenopausal hormone use, screening, and breast cancer: characterization and control of a bias. Epidemiology. 2001;12(4):429-438.
22. Hernán MA, Robins JM. Estimating causal effects from epi-demiological data. J Epidemiol Community Health. 2006;60(7): 578-586.
23. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11(5):550-560.
24. Blackman DK, Bennett EM, Miller DS. Trends in self-reported use of mammograms (1989-1997) and Papanicolaou tests (1991-1997)-Behavioral Risk Factor Surveillance System. MMWR CDC Surveill Summ. 1999;48(6):1-22.
25. Wee CC, McCarthy EP, Davis RB, et al. Obesity and breast cancer screening. J Gen Intern Med. 2004;19(4):324-331.
26. Fontaine KR, Heo M, Allison DB. Body weight and cancer screening among women. J Womens Health Gend Based Med. 2001;10(5):463-470.
27. Sjölander A, Humphreys K, Palmgren J. On informative detection bias in screening studies. Stat Med. 2008;27(14):2635-2650.
28. Cook NR, Cole SR, Hennekens CH. Use of a marginal structural model to determine the effect of aspirin on cardiovascular mortality in the Physicians' Health Study. Am J Epidemiol. 2002;155(11):1045-1053.
29. Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA. 2008;299(9):1036-1045.
30. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
31. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701-1712.
32. Prentice RL, Chlebowski RT, Stefanick ML, et al. Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative Clinical Trial and Observational Study. Am J Epidemiol. 2008;167(12):1407-1415.
33. Prentice RL, Chlebowski RT, Stefanick ML, et al. Estrogen plus progestin therapy and breast cancer in recently post-menopausal women. Am J Epidemiol. 2008;167(10):1207-1216.
34. Kerlikowske K, Miglioretti DL, Buist DS, et al. Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst. 2007;99(17):1335-1339 (Pubitemid 47394172)